Hologic (HOLX)
(Delayed Data from NSDQ)
$79.29 USD
-1.20 (-1.49%)
Updated Nov 7, 2024 03:59 PM ET
After-Market: $79.32 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.29 USD
-1.20 (-1.49%)
Updated Nov 7, 2024 03:59 PM ET
After-Market: $79.32 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Hill Rom Impresses with Q2 Results, Strategic Initiatives
by Zacks Equity Research
On May 18, we issued an updated research report on Hill Rom Holdings, Inc. (HRC).
Mazor Robotics at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of Israel-based developer of robotic technology and products, Mazor Robotics Ltd. (MZOR), rallied to a new 52-week high of $45.64 on May 18.
Exactech (EXAC) Gets FDA Approval for ExactechGPS Application
by Zacks Equity Research
Exactech Inc. (EXAC) recently announced that it has received clearance from the U.S. Food and Drug Administration to market its proprietary ExactechGPS Shoulder Application in US.
Boston Scientific's Symetis Buyout Boosts Structural Heart
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently completed the acquisition of Switzerland-based Symetis SA.
Medtronic's MyCareLink Data on Older Patients Found Positive
by Zacks Equity Research
Medtronic plc (MDT) recently released favorable data on its app-based remote cardiac monitoring.
Halyard Health Announces New Drainage System, Stock Down
by Zacks Equity Research
Halyard Health (HYH), a leading medical technology company, recently announced the availability of the Halyard Enteral Drainage System, a significant addition to the company's comprehensive portfolio of enteral feeding products.
Boston Scientific Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of Natick, MA-based Boston Scientific Corporation (BSX) reached a new 52-week high of $26.76 on May 16, eventually closing a bit lower at $26.48.
Abbott Lab Well Poised on Strong EPD, St. Jude Integration
by Zacks Equity Research
On May 17, we issued an updated research report on Abbott Laboratories (ABT).
Genomic Health Q1 Results Weak, Cancer Test Business Strong
by Zacks Equity Research
On May 16, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).
Edwards Lifesciences SAPIEN 3 Heart Valve Data Positive
by Zacks Equity Research
Edwards Lifesciences Corporation (EW) recently unveiled positive one-year data on its SAPIEN 3 transcatheter heart valve.
Evolent Health (EVH) Prices 7M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) recently announced the pricing of its follow-on public offering of 7.5 million shares of Class A common stock at $24.65 per share.
Genomic Health's (GHDX) Oncotype DX GPS Test Data Positive
by Zacks Equity Research
Genomic Health, Inc. (GHDX), a global cancer company, recently presented positive results for its Oncotype DX Genomic Prostate Score (GPS) test.
Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris
by Zacks Equity Research
Teleflex Inc. (TFX) announced plans to introduce Arrow AC3 Optimus Intra-Aortic Balloon Pump at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) in Paris during May 16--19.
Thermo Fisher (TMO) to Buy Patheon, Expand in Biopharma
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently agreed to acquire Netherlands-based Patheon N.V.
Medtronic ICMs Detect High Rate of AF in Undiagnosed Patients
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently unveiled results from a new clinical study evaluating Insertable Cardiac Monitors (ICMs).
CR Bard (BCR) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of CR Bard (BCR), also known as Bard, rallied to a new 52-week high of $309.16 on May 12. Let us take a look at the key catalysts driving the stock's performance.
Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View
by Zacks Equity Research
Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.
Varian ProBeam Proton System Gets Okayed by Shonin in Japan
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) recently announced that its flagship ProBeam system for proton therapy has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW)
Inogen (INGN) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.
STERIS (STE) Tops Q4 Earnings & Revenues, Issues '18 View
by Zacks Equity Research
STERIS Plc (STE) reported fourth-quarter fiscal 2017 adjusted earnings per share (EPS) of $1.11, up 23.3% from the year-ago quarter.
Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Abiomed Inc. (ABMD), a leading developer, manufacturer and marketer of medical products, reported fourth-quarter fiscal 2017 earnings of 33 cents per share, which were in line with the Zacks Consensus Estimate.
Penumbra (PEN) Q1 Loss Wider than Expected, View Intact
by Zacks Equity Research
Penumbra, Inc. (PEN), that went public in Sep 2015, reported first-quarter 2017 loss of 10 cents per share, comparing unfavorably with earnings of 7 cents year over year.
PetMed (PETS) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
PetMed Express, Inc. (PETS) announced earnings per share of 37 cents for the fourth quarter of fiscal 2017, up 37% from the year-ago quarter's 27 cents.
Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.
Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.